MEDIA RELEASE PR42005
Cellonis' Cell Treatment for Glioma May Prevent Tumor Recurrence and Improve Quality of Life
Significantly
BEIJING, Nov. 3, 2010 /PRNewswire-Asia-AsiaNet/ --
"For brain cancer patients after surgery, the combined DC-CIK and stem cell therapy from Cellonis
Biotechnologies can be a very effective method in preventing cancer recurrence," says renowned cancer
doctor Dr. Dinggang Li. "This is a new hope for cancer patients".
The unique therapy combines the latest stem cell and immuno technology with the benefits of Traditional
Chinese Medicine. Inger Marie Olsen from Norway has recently concluded a cycle of the treatment in Beijing,
and she has been in a stable condition since the first cycle in September 2009.
Dr. Li has been guiding the treatment of Inger. "Inger's general condition has improved very much," he
remarks. "She can now speak, move, eat and sleep much better, she has improved a great deal. I think her
quality of life is almost back to normal."
"I was diagnosed with cancer in 2005," Inger explains in a recent interview. "I had chemotherapy,
radiotherapy and three surgeries, but the cancer still came back. A friend of mine read about this new therapy
on the internet and the people of my town arranged a fund to help me come here."
The Cellonis cancer therapy combines the latest research into cancer stem cells with the advantages of
Traditional Chinese Medicine to create a unique cancer treatment. Dendritic cells, cultured and processed
from blood taken from the patient's body, are loaded with glioma stem cell antigens to create a vaccine that
can activate the immune system to kill cancer cells as well as the cancer stem cells responsible for tumor
initiation and recurrence. Another patient like Inger with glioma who undertook the treatment earlier this year,
Mr. Guy Spavold from Canada, has been in stable condition since April with a good quality of life.
"In my clinical experience patients with an advanced stage of brain tumor after surgery should be given this
therapy to prevent cancer recurrence," continues Dr. Li. "For glioma patients this comprehensive therapy can
be a real benefit and improve their life quality significantly."
Cellonis Biotechnologies focuses on R&D and the clinical application of personalized stem cell therapies
and immunotherapies for patients with diseases including cancer, diabetes and central nervous system
disorders.
CONTACT:
Urs. J. Lienert
COO-International
Cellonis
+86-150-1054-7487
Email: ipsc@cellonis.com
urs.lienert@cellonis.com
SOURCE: Cellonis Biotechnologies Co., Ltd.
Translations:
NEWS 
